1. Combination of ofatumumab and reduced-dose CHOP for diffuse large B-cell lymphomas in patients aged 80 years or older: an open-label, multicentre, single-arm, phase 2 trial from the LYSA group. Issue 1 (January 2017) Authors: Peyrade, Frédéric; Bologna, Serge; Delwail, Vincent; Emile, Jean François; Pascal, Laurent; Fermé, Christophe; Schiano, Jean-Marc; Coiffier, Bertrand; Corront, Bernadette; Farhat, Hassan; Fruchart, Christophe; Ghesquieres, Herve; Macro, Margaret; Tilly, Hervé; Choufi, Bachra; Delarue, Richard; Fi... Journal: Lancet Issue: Volume 4:Issue 1(2017) Page Start: e46 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell–Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial. Issue 12 (20th April 2023) Authors: Thieblemont, Catherine; Phillips, Tycel; Ghesquieres, Herve; Cheah, Chan Y.; Clausen, Michael Roost; Cunningham, David; Do, Young Rok; Feldman, Tatyana; Gasiorowski, Robin; Jurczak, Wojciech; Kim, Tae Min; Lewis, David John; van der Poel, Marjolein; Poon, Michelle Limei; Cota Stirner, Mariana; Ki... Journal: Journal of clinical oncology Issue: Volume 41:Issue 12(2023) Page Start: 2238 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. First‐line treatment of double‐hit and triple‐hit lymphomas: Survival and tolerance data from a retrospective multicenter French study. Issue 3 (29th December 2020) Authors: Laude, Marie‐Charlotte; Lebras, Laure; Sesques, Pierre; Ghesquieres, Herve; Favre, Simon; Bouabdallah, Krimo; Croizier, Carolyne; Guieze, Romain; Drieu La Rochelle, Laurianne; Gyan, Emmanuel; Chin, Roza; Aurran‐Schleinitz, Thérèse; Marouf, Amira; Deau‐Fischer, Bénédicte; Coppo, Paul; Malot, Sandr... Journal: American journal of hematology Issue: Volume 96:Issue 3(2021) Page Start: 302 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Moxetumomab pasudotox as re-treatment for heavily-pretreated relapsed hairy cell leukemia. Issue 11 (19th September 2021) Authors: Yurkiewicz, Ilana R.; Coutre, Steve; Ghesquieres, Herve; Pastan, Ira; Kreitman, Robert J. Journal: Leukemia & lymphoma Issue: Volume 62:Issue 11(2021) Page Start: 2812 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Pembrolizumab for patients with non-Hodgkin lymphoma: phase 1b KEYNOTE-013 study. Issue 1 (2nd January 2023) Authors: Kuruvilla, John; Armand, Philippe; Hamadani, Mehdi; Kline, Justin; Moskowitz, Craig H.; Avigan, David; Brody, Joshua D.; Ribrag, Vincent; Herrera, Alex F.; Morschhauser, Franck; Kanate, Abraham; Zinzani, Pier Luigi; Bitran, Jacob; Ghesquieres, Herve; Schuster, Stephen J.; Farooqui, Mohammed; Mari... Journal: Leukemia & lymphoma Issue: Volume 64:Issue 1(2023) Page Start: 130 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Use of a real-world synthetic control arm for direct comparison of lisocabtagene maraleucel and conventional therapy in relapsed/refractory large B-cell lymphoma. Issue 3 (23rd February 2023) Authors: Van Le, Hoa; Van Naarden Braun, Kim; Nowakowski, Grzegorz S.; Sermer, David; Radford, John; Townsend, William; Ghesquieres, Herve; Menne, Tobias; Porpaczy, Edit; Fox, Christopher P.; Schusterbauer, Claudia; Liu, Fei Fei; Yue, Lihua; De Benedetti, Marc; Hasskarl, Jens Journal: Leukemia & lymphoma Issue: Volume 64:Issue 3(2023) Page Start: 573 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗